Evidence map›Paper›PMID 31243614›Full record

ArticlePurinergic signalling2019

Selective deletion of ENTPD1/CD39 in macrophages exacerbates biliary fibrosis in a mouse model of sclerosing cholangitis.

Sonja Rothweiler, Linda Feldbrügge, Zhenghui Gordon Jiang, Eva Csizmadia, Maria Serena Longhi, Kahini Vaid, Keiichi Enjyoji, Yury V Popov, Simon C Robson

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Purinergic signalling, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed
1.6field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Purinergic Signaling in Non-Parenchymal Liver Cells.International journal of molecular sciences · 2024
    Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Hypoxia-inducible factors and innate immunity in liver cancer.The Journal of clinical investigation · 2020
    Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Sonja RothweilerDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Linda FeldbrüggeDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Zhenghui Gordon JiangDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Eva CsizmadiaDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Maria Serena LonghiDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Kahini VaidDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Keiichi EnjyojiDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA.
Yury V PopovDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA. ypopov@bidmc.harvard.edu.
Simon C RobsonDivision of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center and Harvard Medical School, 330 Brookline Avenue, Dana 501, Boston, MA, 02115, USA. srobson@bidmc.harvard.edu.
Beth Israel Deaconess Medical Center · USHarvard University · USHumboldt-Universität zu Berlin · DE

Funding

STRUCTURE-FUNCTION RELATIONSHIPS IN THE ALIMENTARY TRACTP30DK034854 · NIDDK · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI JONATHAN C KAGAN · 1986 to 2026
$32.4M
Immunomodulatory effects of bilirubin are mediated through aryl hydrocarbon receptor, O2 and purinergic pathwaysR01DK108894 · NIDDK · BETH ISRAEL DEACONESS MEDICAL CENTER · PI LONGHI, MARIA SERENA · 2017 to 2021
$2.0M
NIDDK NIH HHS P30 DK034854NIDDK NIH HHS R01 DK108894NIH HHS 5R01DK108894-02Swiss National Science Foundation P300PB_161098
6 · The paper itself

Abstract

Purinergic signaling is important in the activation and differentiation of macrophages, which play divergent roles in the pathophysiology of liver fibrosis. The ectonucleotidase CD39 is known to modulate the immunoregulatory phenotype of macrophages, but whether this specifically impacts cholestatic liver injury is unknown. Here, we investigated the role of macrophage-expressed CD39 on the development of biliary injury and fibrosis in a mouse model of sclerosing cholangitis. Myeloid-specific CD39-deficient mice (LysMCreCd39

Indexed as

AnimalsAntigens, CDApyraseCholangitis, SclerosingDisease Models, AnimalLiver CirrhosisMacrophagesMiceMice, Inbred C57BLMice, KnockoutPyridines3,5-diethoxycarbonyl-1,4-dihydrocollidineAntigens, CDApyraseCD39 antigenPyridinesCD39Kupffer cellsLiver fibrosisPrimary sclerosing cholangitisPurinergic signaling

Identifiers

PMID31243614
PMCPMC6737175
OpenAlexW2955851425

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.